InspireMD (NSPR)
NASDAQ:NSPR
Want to see NSPR full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.2Last Year’s EPS
-0.26Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presents a mixed picture: strong commercial traction and substantial year-over-year revenue growth (122%), expanding international sales (48% YoY), a large clinical installed base (>70,000 cases), and clear regulatory/clinical pathways (C-GUARDIANS III initiation, expected approvals). Offsetting these positives is a material near-term operational setback — a voluntary U.S. pause/recall of the CGuard Prime 135 delivery system — which led to impairment charges, planned reserves (~$1.35M combined), withdrawal of 2026 revenue guidance, increased operating expenses, and reduced cash versus year-end. Management characterizes the issue as technical (not implant safety), has identified root causes, and expects a path to remediation and relaunch, but timing is uncertain. Overall, the call balances strong growth and long-term opportunity with a meaningful short-term commercial disruption and financial impact.Company Guidance
Clinical Track Record and Physician Demand
CGuard implant used in more than 70,000 cases globally with best-in-class clinical outcomes; management reports strong physician excitement and ongoing demand.
Regulatory and Clinical Milestones
Ongoing positive discussions with FDA; anticipate approval of original CGuard delivery system in Q3 2026 (August window) and expect CGuard Prime 80 TCAR indication in H2 2026; FDA cleared initiation of C-GUARDIANS III trial for SwitchGuard.
TCAR Strategy and Manufacturing Readiness
TCAR strategy remains on track and unaffected by U.S. delivery-system pause; management states manufacturing capacity is ready to support a relaunch with no current constraints.
Cash Position
Cash, cash equivalents and marketable securities of $41.6M as of March 31, 2026, providing runway while international sales continue.
Revenue Growth
Total Q1 2026 revenue of $3.4M, up 122% year-over-year from $1.5M in Q1 2025.
U.S. Launch Traction (Pre-Pause)
U.S. revenue of $1.2M in Q1 2026 driven by CGuard Prime, representing 36% sequential growth versus Q4 2025 during the controlled launch.
International Expansion
International revenue of $2.2M in Q1 2026, up 48% year-over-year vs $1.5M in Q1 2025; foreign exchange contributed ~11% of international growth.
Improved Gross Margins (Non-GAAP)
GAAP gross profit $0.7M (20.2% of revenue) vs 19.1% a year ago; adjusted (non-GAAP) gross profit $1.2M or 34.1% of revenue after excluding a $473k inventory impairment.
NSPR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NSPR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 04, 2026 | $1.17 | $1.10 | -5.98% |
Mar 18, 2026 | $1.79 | $1.79 | 0.00% |
Nov 04, 2025 | $2.29 | $2.13 | -7.21% |
Aug 05, 2025 | $2.67 | $2.45 | -8.24% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does InspireMD (NSPR) report earnings?
InspireMD (NSPR) is schdueled to report earning on Aug 11, 2026, Before Open (Confirmed).
What is InspireMD (NSPR) earnings time?
InspireMD (NSPR) earnings time is at Aug 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NSPR EPS forecast?
NSPR EPS forecast for the fiscal quarter 2026 (Q2) is -0.2.